Novo Nordisk India ne apne Norditropin FlexPro pen ke daam mein **35%** ki bhari katauti ki hai. Company ka maqsad sasti generic vials se competition ko takkar dena aur market share badhana hai.
Novo Nordisk ne apne Norditropin FlexPro growth hormone pens ke daam mein 35% tak ki badi कटौती (cut) ki hai. Ye decision turant effect mein aa gaya hai, jisse 10mg aur 15mg variants ab patients ke liye kaafi saste ho gaye hain.
Naye Daam Kya Hain?
Company ne 10mg pen ki keemat ₹16,836 se ghata kar ₹11,300 kar di hai. Wahi, 15mg variant jo pehle ₹25,254 ka milta tha, ab ₹16,450 mein available hoga. Iska main aim pediatric aur adult patients ko fayda pahunchana hai.
Competition ka Pressure
India mein growth hormone treatment market mein Sun Pharma, Serum Institute aur Reliance Lifesciences jaise bade players hain jo generic vials bechte hain. Ye vials sasti toh hain, lekin inko use karna mushkil hota hai. Novo Nordisk ka FlexPro pen 'easy-to-use' hone ki wajah se premium tha, par ab price kam karke company ne seedhi ladai chhed di hai.
Investors ke liye kya hai?
Price kam karne se sales volume toh badh sakta hai, lekin profit margins par dabav aana pakka hai. Ab dekhna ye hoga ki kya zyaada sales se company apni kamayi recover kar paati hai ya nahi. Agle kuch quarters mein sales growth aur market share ke numbers par sabki nazar rahegi.